The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats

Molecular and Cellular Biochemistry

Volumn 294, Issue 1-2, 2007, Pages 37-44

  Inceli, Meliha Sengezer ^a   Bolkent, Sehnaz ^a   Doger, M Mutluhan ^a   Yanardag, Refiye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chromium; Creatinine; Glutathione; Hyperlipidemia; Lipid peroxidation; Morphology; Niacin; Rat; Renal tissue; Urea

Indexed keywords

CHOLESTEROL; CHOLIC ACID; CHROMIUM CHLORIDE; CREATININE; GLUTATHIONE; NICOTINIC ACID; SUNFLOWER OIL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ELECTRON MICROSCOPY; FEEDING; FEMALE; HYPERLIPIDEMIA; KIDNEY DISEASE; KIDNEY PARENCHYMA; LIPID DIET; LIPID PEROXIDATION; NONHUMAN; RAT; RENAL PROTECTION; UREA BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; CHROMIUM; CREATININE; DIETARY FATS; DRUG THERAPY, COMBINATION; FEMALE; GLUTATHIONE; HYPERLIPIDEMIAS; KIDNEY; LIPID PEROXIDATION; NIACIN; RANDOM ALLOCATION; RATS; UREA;

ANIMALIA; RATTUS;

EID: 33846674641     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9211-x     Document Type: Article

References (62)

1. Campbell JD: Lifestyle, minerals and health. Med Hypotheses 57: 521-531, 2001
2. Snively CS, GutierPez C: Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician 70: 1921-1928, 2004
3. Kamanna VS, Roh DD, Kirschenbaum MA: Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus. Histol Histopathol 13: 169-179, 1998
4. Zambon A, Hokanson JE, Brown BG, Brunzell JD: Evidence for a new pathophysiological mechanism for coronary artery disease regression. Am Heart Assoc 99: 1959-1964, 1999
5. Imai Y, Suzuki H, Saito T, Tsuji I, Abe K, Saruta T: The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Clin Exp Hypertens 21: 1345-1355, 1999
6. Kumai T, Oonuma S, Kitaoka Y, Tadokoro M, Kobayashi S: Biochemical and morphological characterization of spontaneously hypertensive hyperlipidaemic rats. Clin Exp Pharmacol Physiol 30: 537-544, 2003
7. Madore F: Cardiac risk factors in renal disease. Med Sci 20: 1100-1103, 2004
8. Simonoff M: Chromium deficiency and cardiovascular risk. Cardiovas Res 18: 591-596, 1984
9. Bourn DM, Gibson RS Martinez OB, Macdonald AC: The effect of chromium supplementation on serum lipid levels in a selected sample of canadian postmenopausal women. Biol Trace Elem Res 9: 197-205, 1986
10. Anderson RA: Chromium metabolism its role in disease processes in man. Clin Physiol Biochem 4: 31-41, 1986
11. Vincent JB: Elucidating a biological role for chromium at a molecular level. Acc Chem Res 33: 503-510, 2000
12. Cohen MD, Kargacin B, Klein CB, Costa M: Mechanisms of chromium carcinogenicity and toxicity. Crit Rev Toxicol 23: 255-281, 1993
13. Morris B, Peacey SR, Macneil S, Gray T: Enhacement in insulin sensitivity in healthy volunteers following supplementation with chromium picolinate. Med Biochem 1: 65-72, 1998
14. Davies S, McLaren Howard J, Hunnisett A, Howard M: Age-related decreases in chromium levels in 51,665 hair, sweat and serum samples from 40,872 patients-implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 46: 469-473, 1997
15. Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willett WC, Hu FB: Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 27: 2211-2216, 2004
16. Anderson RA: Nutritional role of chromium. Sci Total Environ 17: 13-29, 1981
17. Racek J: Chromium as an essential element. Cas Lek Cesk 142: 335-339, 2003
18. Offenbacher EG, Pi-Sunyer FX: Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29: 919-925, 1980
19. Wang MM, Fox EA, Stoecker BJ, Menendez CE, Chan SB: Serum cholesterol of adults supplemented with brewer's yeast or chromium chloride. Nutr Res 9: 989-998, 1989
20. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95: 69-76, 1992
21. Goldberg AC: Clinical trial experience with extended-release niacin (Niaspan): Dose- escalation study. Am J Cardiol 82: 35U-38U, 1998
22. 22 Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM: Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2: 64-71, 2000
23. 23 Tavintharan S, Kashyap Benefits ML: The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 3: 74-82, 2001
24. 24 Morgan JM, Capuzzi DM, Guyton JR: A new extended-release niacin (niaspan): Efficiacy, tolerabity, and safety in hypercholesterolemic patients. Am J Cardiol 82: 29U-34U, 1998
25. 25 Goldberg A, Alagona P, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P: Multiple-dose efficiacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85: 1100-1105, 2000
26. Anderson RA, Polansky MM, Bryden NA, Patterson KY, Veillon C, Glinsmann WH: Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. J Nutr 113: 276-281, 1983
27. Roeback JR, Hla KM, Chambles LE, Fletcher RH: Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. Ann Intern Med 115: 917-924, 1991
28. Anderson RA, Bryden NA, Polansky MM, Gautschi, K: Dietary chromium effects on tissue chromium concentrations and chromium absorbtion in rats. J Trace Elem Exp Med 9: 11-25, 1996
29. Anderson RA, Bryden NA, Evock-Clover CM, Steele NC: Benificial effects of chromium on glucose and lipid variables in control and somatotropin-treated pigs are associated with increased tissue chromium and altered tissue cooper, iron, and zinc. J Anim Sci 75: 657-661, 1997
30. Kegley EB, Spears JW, Eisemann JH: Performance and glucose metabolism in calves fed a chromium-nicotinic acid complex or chromium chloride. J Dairy Sci 80: 1744-1750, 1997
31. Rikans LL, Arata D, Cederquist DC: Fatty livers produced in albino rats by excess niacin in high fat diets. II Effect of choline supplements. J Nutr 85: 107-112, 1965
32. Cohen L, Morgan J: Effectiveness of individualized long term therapy with niacin and probucol in reduction of serum cholesterol. J Fam Practice 26: 145-150, 1988
33. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VMG, Zhao X-Q, Albers JJ, Knoop RH: Moderato dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol<100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 80: 111-115, 1997
34. Guyton JR, Cappuzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 82: 82U-84U, 1998
35. Preuss HG, Wallerstedt D, Talpur N, Tutuncuoglu SO, Echard B, Bui M, Bagchi D: Effect of niacin-bound chromium and grapeseed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: A pilot study. J Med 31: 227-246, 2000
36. Ledwozyw A, Michalak J, Stepien A, Kadziolka A: The relationship plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 155: 275-284, 1986
37. Beutler E: Glutathione in red cell metabolism a manual of biochemical methods, 2nd edn. Grune and Stratton, New York, 1975, pp 112-114
38. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951
39. Barker SB: The direct colorimetric determination of urea in blood and urine. J Biol Chem 152: 453-463, 1944
40. Bonsnes RW, Taussky, HH: On the colorimetric determination of creatinine by the Jaffe Reaction. J Biol Chem 158: 581-591, 1945
41. Hintze JL: Copyright C. 865, East 400. North Kaysville, Utah, 84,037(801), 546-0445, 1986
42. Tunez L, Munoz MC, Feijoo-Lopez AL, Valdvira E, Bujalance-Arenas L, Montilla P: Effect of melatonin on hyperlipidemic nephropathy under constant light exposure. J Physiol Biochem 58: 109-114, 2002
43. Rukkumani R, Sri, Balasubashini M, Vishwanathan P, Menon VP: Comparative effects of curcumin and photo-irradiated curcumin on alcohol-and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacol Res 46: 257-264, 2002
44. Bolkent S, Yanardag R, Bolkent S, Doger MM: Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats. Biol Trace Elem Res 101: 219-230, 2004
45. Yanardag R, Peksel A, Yeşilyaprak B. Doger MM, Arisan-Atac I: Effects of a combination of niacin and chromium (III)-chloride on the skin and lungs of hyperlipemic rats. Biol Trace Elem Res 103: 249-260, 2005
46. Scheuer H, Gwinner W, Hohbach J, Gröne EF, Brandes RP, Malle E, Olbricht CJ, Walli AK, Gröne HJ: Oxidant sterss in hyperlipidemia- induced renal damage. Am J Physiol Renal Physiol 278: F63-F74, 2000
47. Mühlfeld AS, Spencer MW, Hudkins KL, LeBoeuf RC, Alpers CE: Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int 66: 1393-1402, 2004
48. Hasegawa N, Yamda N, Mori M: Powdered green tea has antilipogenic effect on Zucker rats fed a high-fat diet. Phytother Res 17, 477-480, 2003
49. Devi R, Sharma DK: Hypolipidemic effect of different extracts of clerodendron colebrookianum Walp in normal and high-fat diet fed rats. J Etnopharmacol 90: 63-68, 2004
50. Yamaguchi Y, Kagota S, Nakamura K, Shinozuka K, Kunitomo, M: Inhibitory effects of water extracts from fruiting bodies of cultured Cordyceps sinensis on raised serum lipid peroxide levels and aortic cholesterol deposition in atherosclerotic mice. Phytother Res 14: 650-652, 2000
51. Ravi Deepa P, Varalakshmi P: Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis. Clin Chim Acta 339: 105-115, 2004
52. Montilla P, Tunez I, Munoz MC, Lopez A, Soria JV: Hyperlipidemic nephropathy induced by adriamycin: Effect of melatonin administration. Nephron 76: 345-350, 1997
53. Malarkodi KP, Balachandar AV, Varlakshmi P: The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem 247: 139-145, 2003
54. 51Cr picolinate in a rat model. Trace Elem Electroly 11: 182-186, 1994
55. Stearns DM, Wise Sr JP, Patierno SR, Wetterhahn KE: Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 9: 1643-1649, 1995
56. Riales R, Albrink MJ: Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 34: 2670-2678, 1981
57. Preuss HG, Grojec PL, Lieberman S, Anderson RA: Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Clin Nephrol 47: 325-330, 1997
58. Vinson JA, Mandarano MA, Shuta DL, Bagchi M, Bagchi D: Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model. Mol Cell Biochem 240: 99-103, 2002
59. Preuss HG, Grojec PL, Lieberman S, Anderson RA: Effects of different chromium compounds on blood pressure and lipid peroksidation in spontaneously hypertensive rats. Clin Nephrol 47: 325-330, 1997
60. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M: Contrasting Effects of unmodified and time-release froms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34: 642-650, 1985
61. Angelin B, Eriksson M, Einarsson K: Combined treatment with colestyramine and nicotinic acid in heterozygous familial hypercolesterolaemia: Effects on biliary lipid composition. Eur J Clin Invest 16: 391-396, 1986
62. Figge HL, Figge J, Souney PF, Mutnick AH, Sacks F: Nicotinic acid: A review of its clinical use in the treatment of lipid disorders. Ther Rev 8: 287-294, 1988